Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation.
SAN FRANCISCO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal...
THB335 Phase 1 SAD/MAD clinical trial on track to deliver clinical results in 1Q’25 Strong financial position with cash and cash equivalents totaling $296.1 million as of September 30, 2024 SAN...
SAN FRANCISCO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal...
SAN FRANCISCO, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Third Harmonic Bio, Inc. (Nasdaq: THRD), a clinical-stage biopharmaceutical company focused on advancing the next wave of medicine for dermal...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.5 | -17.5315568022 | 14.26 | 14.26 | 10.1 | 140571 | 12.02729828 | CS |
4 | -1.2 | -9.25925925926 | 12.96 | 15.5 | 10.1 | 218216 | 13.72433567 | CS |
12 | -0.22 | -1.83639398998 | 11.98 | 16.02 | 10.1 | 215541 | 13.47137007 | CS |
26 | -2.64 | -18.3333333333 | 14.4 | 16.94 | 10.1 | 140805 | 13.29007837 | CS |
52 | 4.97 | 73.1958762887 | 6.79 | 16.94 | 6.79 | 144007 | 11.7889639 | CS |
156 | -29.11 | -71.225838023 | 40.87 | 40.87 | 3.75 | 113662 | 9.31409839 | CS |
260 | -29.11 | -71.225838023 | 40.87 | 40.87 | 3.75 | 82594 | 9.31409839 | CS |
귀하가 조회한 주식이 이 박스에 나타나며 쉽게 최근 시세로 돌아갈 수 있습니다.
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관